Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arna H Arnardottir

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Drug Safety|October 11, 2011
Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment ReportsArna H Arnardottir, Flora M Haaijer-Ruskamp, Sabine M J Straus, et al.
Frontiers in Pharmacology|March 15, 2021
Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference StudySonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, et al.
British Journal of Clinical Pharmacology|April 20, 2011
Additional safety risk to exceptionally approved drugs in Europe?Arna H Arnardottir, Flora M Haaijer-Ruskamp, Sabine M J Straus, et al.
British Journal of Clinical Pharmacology|December 4, 2014
Understanding drug preferences, different perspectivesPeter G M Mol, Arna H Arnardottir, Sabine M J Straus, et al.
Drug Safety|September 20, 2013
Post-approval safety issues with innovative drugs: a European cohort studyPeter G M Mol, Arna H Arnardottir, Domenico Motola, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Drug Safety|October 11, 2011
Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment ReportsArna H Arnardottir, Flora M Haaijer-Ruskamp, Sabine M J Straus, et al.
Frontiers in Pharmacology|March 15, 2021
Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference StudySonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, et al.
British Journal of Clinical Pharmacology|April 20, 2011
Additional safety risk to exceptionally approved drugs in Europe?Arna H Arnardottir, Flora M Haaijer-Ruskamp, Sabine M J Straus, et al.
British Journal of Clinical Pharmacology|December 4, 2014
Understanding drug preferences, different perspectivesPeter G M Mol, Arna H Arnardottir, Sabine M J Straus, et al.
Drug Safety|September 20, 2013
Post-approval safety issues with innovative drugs: a European cohort studyPeter G M Mol, Arna H Arnardottir, Domenico Motola, et al.
Pageof 1